Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Comparative Immunogenicity Of Na-Gst-1 Human Hookworm Vaccine With Synthetic Glucopyranosyl Lipid Adjuvant (Gla) In Balb/C Mice, Amar R. Jariwala, Brian Keegan, Jordan L. Plieskatt, Maria Elena Bottazzi, Peter J. Hotez, Jeffrey M. Bethony
Comparative Immunogenicity Of Na-Gst-1 Human Hookworm Vaccine With Synthetic Glucopyranosyl Lipid Adjuvant (Gla) In Balb/C Mice, Amar R. Jariwala, Brian Keegan, Jordan L. Plieskatt, Maria Elena Bottazzi, Peter J. Hotez, Jeffrey M. Bethony
Microbiology, Immunology, and Tropical Medicine Posters and Presentations
More than 740 million people worldwide are infected with Hookworm. Hookworm infection is most prevalent in the poorest of the poor populations of the world, and has serious health effects. Hookworm infection causes blood loss leading to iron deficiency anemia and protein energy malnutrition, which results in a compromised immune response. Consequently, the target human population suffers from an increased susceptibility to infectious diseases including hookworm infection. We have developed recombinant adult hookworm vaccines against hookworm infection to break this vicious cycle. Toll-like receptor (TLR) 4 agonist are known to boost immune response in healthy and immunocompromised individuals. We believe …
Potency Testing For Ntd Vaccines: Determining Relative Potency For The Na-Gst-1 Human Hookworm Vaccine, Amar R. Jariwala, Brian Keegan, Pavithra Raghavendra, Jordan L. Plieskatt, Maria Elena Bottazzi, Peter J. Hotez, Jeffrey M. Bethony
Potency Testing For Ntd Vaccines: Determining Relative Potency For The Na-Gst-1 Human Hookworm Vaccine, Amar R. Jariwala, Brian Keegan, Pavithra Raghavendra, Jordan L. Plieskatt, Maria Elena Bottazzi, Peter J. Hotez, Jeffrey M. Bethony
Microbiology, Immunology, and Tropical Medicine Posters and Presentations
Over the next decade, a new generation of vaccines will target the neglected tropical diseases (NTDs) . The goal of most NTD vaccines will be to reduce the morbidity and decrease the chronic debilitating nature of these often-forgotten infections - outcomes that are hard to measure in the traditional potency-testing paradigm . The absence of measurable correlates of protection, a lack of permissive animal models for lethal infection, and a lack of clinical indications that do not include the induction of sterilizing immunity required us to reconsider the traditional bioassay methods for determining vaccine potency . Owing to these limitations, …